CytoSorbents Prepares to Showcase Innovations at Jefferies Healthcare Conference in London

CytoSorbents to Present at the Jefferies Global Healthcare Conference

Overview

CytoSorbents Corporation, listed on NASDAQ as CTSO, is recognized as a frontrunner in the management of critical, life-threatening conditions primarily in ICU and cardiac surgery settings. The company is set to present its innovative solutions at the prestigious Jefferies Global Healthcare Conference, scheduled to take place from November 17 to 20, 2025, in London.

Presentation Details

The CytoSorbents team plans to showcase their cutting-edge blood purification technology on November 18, 2025, at 12:30 PM GMT / 7:30 AM ET. This event will feature presentations from the management team and one-on-one meetings with investors, providing an excellent opportunity for engagement and collaboration. Those interested in viewing the presentation can access it through a live webcast available on the company’s investor relations page.

Company Insights

Founded with a mission to address severe medical conditions, CytoSorbents has developed proprietary blood purification technologies that utilize biocompatible and highly porous polymer beads. These beads work by filtering out toxic substances from blood and other bodily fluids via processes like pore capture and surface adsorption.

The cartridges filled with these beads integrate seamlessly with existing hospital equipment such as dialysis machines and heart-lung machines. This integration allows for the continuous recirculation of blood outside the body, permitting the removal of harmful agents before the treated blood is returned to the patient.

Critical Applications

CytoSorbents' technology has vital applications in two key areas:
1. Surgical Procedures: The extraction of blood thinners during operations, particularly in cardiothoracic surgeries, helps mitigate the risk of excessive bleeding.
2. Critical Illness Treatment: The purification systems are influential in removing inflammatory agents and toxins associated with critical illnesses, which can cause severe complications like sepsis and organ failure.

The company's lead product, CytoSorb®, is already CE marked in the European Union and has been deployed across more than 70 countries. With a record of almost 300,000 devices utilized globally, CytoSorb has also gained Emergency Use Authorization from the FDA for treating critically ill COVID-19 patients.

Progress and Future Endeavors

In addition to CytoSorb, the company is working on the DrugSorb™-ATR system aimed at reducing perioperative bleeding caused by anticoagulants during high-risk surgeries. This investigational device has already earned two Breakthrough Device Designations from the FDA, indicating its potential as a transformative treatment.

Despite facing regulatory challenges, CytoSorbents is actively pursuing approvals and is equipped with a robust portfolio of patents to protect its innovations, which include various blood purification products like ECOS-300CY®, DrugSorb™, and ContrastSorb.

Conclusion

With the upcoming presentation at the Jefferies Global Healthcare Conference, CytoSorbents is poised to make significant strides in the critical care sector. The company's focus on innovative blood purification technologies aims not only to enhance patient recovery rates but also to redefine standards in critical healthcare solutions. For more detailed information on their offerings and research, visit Cytosorbents' official website.